文献速递腹部CTMR

CT/MRI LI-RADS v2018在非肝硬化丙型肝炎病毒感染中的诊断效能

Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic hepatitis C virus infection.
PubMed 文献 · Abdom Radiol (NY) · 2024-09-26

回顾性单中心研究纳入43例非肝硬化HCV感染患者的66个观察灶,评估LI-RADS v2018诊断HCC和整体恶性肿瘤的效能。LR-5诊断HCC的敏感度74-90%、特异度94-100%、准确率80-91%,LR-5/LR-M/LR-TIV联合诊断整体恶性肿瘤的敏感度87-98%、特异度92-100%、准确率89-97%,最终分类的读者间一致性为显著。结论认为CT/MRI LI-RADS v2018 criteria可应用于非肝硬化HCV患者,特异度接近完美。

要点

  • LR-5诊断HCC的敏感度74-90%、特异度94-100%、准确率80-91%。
  • LR-5/LR-M/LR-TIV联合诊断整体恶性肿瘤的敏感度87-98%、特异度92-100%、准确率89-97%。
  • LR-5对HCC的阳性预测值为98-100%,LR-M对整体恶性肿瘤的阳性预测值为100-100%。

核心结论

  • CT/MRI LI-RADS v2018 criteria可应用于非肝硬化HCV患者,特异度接近完美。

研究设计与样本

  • 回顾性、经IRB批准的单中心研究,纳入43例成人患者(11例女性、32例男性,中位年龄65岁)的66个观察灶。
  • 所有患者于2010年至2023年接受肝脏方案CT或MRI检查,有HCV感染,且基于组织病理学无肝硬化。
  • 三名委员会认证的腹部放射科医师在不知组织病理学和影像随访的情况下评估每个观察灶的主要特征和最终LI-RADS分类,并计算加权kappa的读者间一致性。

诊断标准与关键数值

  • LR-5诊断HCC的敏感度74-90%、特异度94-100%、准确率80-91%。
  • LR-5、LR-M或LR-TIV联合诊断整体恶性肿瘤的敏感度87-98%、特异度92-100%、准确率89-97%。
  • HCC的阳性预测值:LR-1为0-0%、LR-2为0-0%、LR-3为0-33%、LR-4为57-100%、LR-5为98-100%、LR-M为25-50%、LR-TIV为83-100%。
  • 整体恶性肿瘤的阳性预测值:LR-1为0-0%、LR-2为0-0%、LR-3为0-33%、LR-4为57-100%、LR-5为98-100%、LR-M为100-100%、LR-TIV为100-100%。
  • 主要特征的读者间一致性为中等至显著,最终分类的读者间一致性为显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the diagnostic performance of LI-RADS among patients with non-cirrhotic hepatitis C virus (HCV) infection.

METHODS: This retrospective, IRB-approved, single-center study included 66 observations from 43 adult patients (11 women, 32 men; median age 65 years). All patients received liver protocol CT or MRI from 2010 to 2023, had HCV, and did not have cirrhosis based on histopathology. Three board-certified abdominal radiologists blinded to histopathology and imaging follow-up assessed each observation for major features and final LI-RADS category, and inter-reader agreements with weighted kappa were calculated. The positive predictive value, sensitivity, specificity, and accuracy of in diagnosing HCC and overall malignancy was calculated.

RESULTS: Of the 66 observations, 53 (80%) were malignant and 13 (20%) were benign. Positive predictive value for HCC was 0-0% for LR-1, 0-0% for LR-2, 0-33% for LR-3, 57-100% for LR-4, 98-100% for LR-5, 25-50% for LR-M, and 83-100% for LR-TIV. Positive predictive value for overall malignancy was 0-0% for LR-1, 0-0% for LR-2, 0-33% for LR-3, 57-100% for LR-4, 98-100% for LR-5, 100-100% for LR-M, and 100-100% for LR-TIV. For LR-5 in identifying HCC, sensitivity ranged from 74 to 90%, specificity from 94 to 100%, and accuracy from 80 to 91%. For the composite of LR-5, LR-M, or LR-TIV in identifying overall malignancy, sensitivity was 87-98%, specificity was 92-100%, and accuracy was 89-97%. The inter-reader agreement for major features varied from moderate to substantial, with substantial agreement for the final category.

CONCLUSION: CT/MRI LI-RADS v2018 criteria can be applied to non-cirrhotic HCV patients with near-perfect specificity.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Cao JJ, Shon A, Yoon L, et al. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic hepatitis C virus infection. Abdom Radiol (NY). 2024. PMID: 39400590. doi:10.1007/s00261-024-04589-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。